Biomet Deferred Prosecution Agreement 2007

Biomet Deferred Prosecution Agreement 2007: A Comprehensive Overview

The medical device industry is under constant scrutiny for compliance with legal and regulatory requirements. The Biomet deferred prosecution agreement (DPA) of 2007 is a prime example of the consequences that can result from violating such laws. In this article, we will delve into the details of the Biomet DPA, its background, the legal implications for Biomet and the broader medical device industry, as well as the lessons to be learnt from this case.

What is a Deferred Prosecution Agreement?

Before we look into the Biomet DPA, let`s first understand what a deferred prosecution agreement is. A deferred prosecution agreement is a legal settlement between a prosecutor and a defendant that enables the defendant to avoid criminal prosecution by agreeing to fulfill certain conditions set forth in the agreement. In essence, it is an alternative to criminal prosecution that offers companies the opportunity to rectify their wrongdoings without having to face severe legal repercussions.

Background of the Biomet DPA

In 2007, Biomet Inc., a medical device manufacturer, faced allegations of paying kickbacks to surgeons who used their products. The kickbacks were disguised as consulting fees, research grants, and other forms of compensation. The scheme was intended to induce these physicians to use Biomet`s products in their surgical procedures.

The US Department of Justice (DoJ) initiated an investigation into Biomet`s practices, and the company cooperated with the authorities in the investigation. In 2012, the company reached a settlement with the DoJ by agreeing to pay $22.7 million as penalties and to fulfill certain conditions as part of the Biomet deferred prosecution agreement.

Legal Implications for Biomet and the Medical Device Industry

The Biomet DPA highlighted the importance of compliance with anti-kickback laws and regulations. The Anti-Kickback Statute (AKS) makes it illegal to offer, pay, solicit, or receive any form of compensation in exchange for referrals or the use of certain medical products or services. Violating the AKS can result in severe legal and financial repercussions, including criminal prosecution, civil penalties, and exclusion from participating in federal health care programs.

The Biomet DPA served as a warning to other companies in the medical device industry to ensure compliance with the AKS and other applicable laws and regulations. It also emphasized the need for effective compliance programs to prevent and detect violations of such laws.

Lessons to be Learnt from the Biomet DPA

The Biomet DPA provides valuable lessons to companies in the medical device industry. Firstly, compliance with laws and regulations should be a top priority for companies in this industry. A comprehensive and effective compliance program should be implemented and regularly reviewed to ensure ongoing compliance.

Secondly, companies should cooperate with law enforcement agencies during investigations to avoid severe legal repercussions. The Biomet case demonstrated that cooperating with the authorities can result in a more favorable legal outcome.

Lastly, companies should be transparent in their dealings and avoid any practices that may be perceived as unethical or illegal. The Biomet DPA serves as a reminder that companies can face severe legal and financial consequences for non-compliance with laws and regulations.


The Biomet deferred prosecution agreement of 2007 was a landmark case for the medical device industry. Companies in this sector must acknowledge the importance of compliance with laws and regulations and ensure that effective compliance programs are in place. The Biomet case serves as a reminder that non-compliance can result in severe legal and financial repercussions for companies in the medical device industry.